These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 3528926)

  • 1. [Adjuvant hormone therapy of breast neoplasms. A critical review of the literature and perspectives].
    Boccardo F; Valenti G; De Menech R; Zanardi S
    Minerva Ginecol; 1986; 38(7-8):659-65. PubMed ID: 3528926
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review.
    Poole R; Paridaens R
    Curr Opin Oncol; 2007 Nov; 19(6):564-72. PubMed ID: 17906453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition.
    Spicer J; Ellis P
    Cancer Lett; 2007 Apr; 248(2):165-74. PubMed ID: 16919870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Aromatase inhibitors in the adjuvant therapy of breast cancer].
    Bauerschlag D; Schem C; Maass N; Jonat W
    Gynakol Geburtshilfliche Rundsch; 2005 Jun; 45(3):132-6. PubMed ID: 15990437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tamoxifen for the prevention of breast cancer: yes.
    Vogel VG; Saenz M
    Important Adv Oncol; 1995; ():187-200. PubMed ID: 7672805
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of estrogen dependency of human breast cancers. II. Clinical evaluation of tamoxifen in advanced primary and recurrent breast cancer.
    Nishiki M; Yamane M; Amano K; Yasuda K; Okumichi T; Ezaki H
    Hiroshima J Med Sci; 1984 Jun; 33(2):163-6. PubMed ID: 6480380
    [No Abstract]   [Full Text] [Related]  

  • 7. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of cytostatic therapy on bone metabolism].
    Heytmanek G; Sevelda P; Enzelsberger H; Metka M; Kubista E
    Gynakol Rundsch; 1988; 28 Suppl 2():193-5. PubMed ID: 3069624
    [No Abstract]   [Full Text] [Related]  

  • 9. [Anti-aromatase acting drugs].
    Diedrich K
    Krankenpfl J; 2005; 43(4-6):150-1. PubMed ID: 16171094
    [No Abstract]   [Full Text] [Related]  

  • 10. Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer.
    Harvey HA; Lipton A; White DS; Santen RJ; Boucher AE; Shafik AS; Dixon RJ
    Cancer Res; 1982 Aug; 42(8 Suppl):3451s-3453s. PubMed ID: 6177405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant endocrine therapy for perimenopausal women with early breast cancer.
    Ortmann O; Cufer T; Dixon JM; Maass N; Marchetti P; Pagani O; Pronzato P; Semiglazov V; Spano JP; Vrdoljak E; Wildiers H
    Breast; 2009 Feb; 18(1):2-7. PubMed ID: 19036588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prospective randomized study of the efficacy of adjuvant hormone therapy in patients with breast cancer].
    Semiglazov VF; Moiseenko VM; Ivanova OA
    Vopr Onkol; 1986; 32(8):31-4. PubMed ID: 3532535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Symposium on the management of early breast cancer (stages I and II). Part II: Clinical experience with treatment methods. 5. Adjuvant endocrine therapy.
    Palshof T
    Can J Surg; 1981 Jul; 24(4):379-84. PubMed ID: 7023634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RE: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.
    Sgroi DC; Haber DA; Ryan PD; Ma XJ; Erlander MG
    Cancer Cell; 2004 Nov; 6(5):445. PubMed ID: 15542428
    [No Abstract]   [Full Text] [Related]  

  • 15. [Tamoxifen: modern drug therapy of estrogen-dependent breast tumors].
    Jovanović-Mićić D; Beleslin DB; Nikolić SS
    Med Pregl; 1996; 49(7-8):287-90. PubMed ID: 8926945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying menopause in breast cancer patients: considerations and implications.
    Clemons M; Simmons C
    Breast Cancer Res Treat; 2007 Aug; 104(2):115-20. PubMed ID: 17061039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen, raloxifene and the prevention of breast cancer.
    Bentrem DJ; Craig Jordan V
    Minerva Endocrinol; 2002 Jun; 27(2):127-39. PubMed ID: 11961504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant treatment of breast cancer.
    Akerley WL
    R I Med; 1995 Sep; 78(9):250-3. PubMed ID: 7579720
    [No Abstract]   [Full Text] [Related]  

  • 19. Commentary: optimal adjuvant endocrine therapy of postmenopausal breast cancer.
    Cunnick G; Mokbel K
    Int J Fertil Womens Med; 2005; 50(5 Pt 1):197-8. PubMed ID: 16468468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamoxifen--the story so far.
    Fraser SC; Brooks MD
    Br J Clin Pract; 1989 Oct; 43(10):380-2. PubMed ID: 2698243
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.